Figure 4.
Anti‐IL‐1β antibody treatment prolongs the survival of IAV‐infected mice. (a–d) C57BL/6 mice were infected intranasally with HKx31 of 105 PFU and intranasally treated with anti‐IL‐1β or control IgG antibodies. Antibody treatment was commenced on (a, b) day 1 or (c, d) day 3 following infection. Mice received additional treatments in 48‐h intervals as indicated with arrows. (a, c) Mice were assessed daily for clinical signs of disease (score of 0–3) as described in the “Methods” section. Data represent the mean ± s.e.m. **P < 0.01, Student’s t‐test. (b, d) Survival curves are shown. Mice displaying a clinical score of 3 (ruffled fur, reduced mobility or rapid breathing) or 20% or more weight loss were euthanized. **P < 0.01, ***P < 0.001, Mantel–Cox log‐rank test. (a–d) Data are from two independent experiments were pooled (n = 8). IAV, influenza A virus; Ig, immunoglobulin; IL, interleukin; PFU, plaque‐forming units.